You are here

RNAi

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Endpoints

Alzheimer's disease

Flag link:

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Yahoo/Zacks.com

hereditary ATTR amyloidosis

Flag link:

Alnylam outshines Ionis with RNAi drug

Alnylam outshines Ionis with RNAi drug

BioPharma Dive

Ionis Pharmaceuticals

Flag link:

Dicerna and Boehringer partner on RNAi treatment for NASH

Dicerna and Boehringer partner on RNAi treatment for NASH

Endpoints

Boehringer Ingelheim

Flag link:

A drug 15 years in the making: Alnylam's quest to prove RNAi

A drug 15 years in the making: Alnylam's quest to prove RNAi

BioPharma Dive

Flag link:

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Stat

familial amyloid polyneuropathy

Flag link:

Alnylam review turns up no clear answers on revusiran deaths

Alnylam review turns up no clear answers on revusiran deaths

BioPharma Dive

Flag link:

EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts

EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts

Fierce Biotech

artificial intelligence

Silence Therapeutics

Flag link:

Alnylam lines up Phase 3 for another RNAi drug

Alnylam lines up Phase 3 for another RNAi drug

BioPharma Dive

acute hepatic porphyrias

Flag link:

Alnylam shares crater after deaths force investigators to scrap PhIII RNAi drug

Alnylam shares crater after deaths force investigators to scrap PhIII RNAi drug

Endpoints

clinical trials

Flag link:

Could Alnylam Pharmaceuticals Change Medicine as We Know It?

Could Alnylam Pharmaceuticals Change Medicine as We Know It?

Motley Fool

Flag link:

Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug

Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug

Fierce Biotech

Flag link:

Tekmira's Ebola drug comes up short in Phase II

Tekmira's Ebola drug comes up short in Phase II

Fierce Biotech

Flag link:

Alnylam's star RNAi drug keeps the pace on the way to Phase III

Alnylam's star RNAi drug keeps the pace on the way to Phase III

Fierce Biotech

Flag link:

Silence Therapeutics raises $58 million to advance R&D

Silence Therapeutics raises $58 million to advance R&D

BioPharma Dive

Silence Therapeutics

Flag link:

Novartis sells its RNAi cast-offs from Alnylam in $35M fire sale to Arrowhead

Novartis sells its RNAi cast-offs from Alnylam in $35M fire sale to Arrowhead

Fierce Biotech

Arrowhead Research

Flag link:

Alnylam reports results from Phase 2 revusiran trial

Alnylam reports results from Phase 2 revusiran trial

Seeking Alpha

TTR cardiac amyloidosis

Flag link:

Study Suggests RNAi Drug Has Potential in Ebola Treatment

Study Suggests RNAi Drug Has Potential in Ebola Treatment

WSJ Pharmalot

Tekmira Pharmaceuticals

Flag link:

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

24/7 Wall St

Arrowhead Research

Gilead Sciences

Intercept Pharmaceuticals

Vertex Pharmaceuticals

Flag link:

Is This the Crown Jewel of the ISIS Pipeline?

Is This the Crown Jewel of the ISIS Pipeline?

Motley Fool

Isis Pharmaceuticals

Flag link:

Pages